All In Biotech

Drug Trial Radar · NCT01566552

Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis

Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India.

Last checked: Nov 20, 2026Latest source record: Jan 22, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

1,300

Planned (sponsor's estimate)

Start

Jun 2014

Primary completion

Dec 2016

Study completion Dec 2017

Sponsor

Lead sponsor
Banaras Hindu UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rajendra Memorial Research Institute of Medical Sciences
First posted
Mar 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 5 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is designed to determine the use of delivering point of care, rapid diagnosis with rK39 and treatment with AmBisome single dose of 10 mg/kg when administrated in the Primary Health Center (PHC) settings with regard to operational feasibility, safety and final cure rate at 6 months after end of treatment. Point of care diagnosis and treatment (PCDT) at the PHC level would bring the best available interventions closer to the patients with visceral leishmaniasis (VL) whose villages are within several kilometers of the PHC. This would support the VL elimination program in the Indian subcontinent.

Conditions

  • Visceral Leishmaniasis

Interventions

  • AMBISOMEDrug

    SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CLINICAL CURETime frame: 24 MONTHS

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kala Azar Medical Research Center

    Muzaffarpur, Bihar, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.